Oral administration of Bifidobacterium bifidum G9-1 alleviates rotavirus gastroenteritis through regulation of intestinal homeostasis by inducing mucosal protective factors

• Tomohiro Kawahara ,

  * E-mail: kawahara_tomohiro@biofermin.co.jp

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Yutaka Makizaki,

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Yosuke Oikawa,

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Yoshiki Tanaka,

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Ayako Maeda,

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Masaki Shimakawa,

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Satoshi Komoto,

  Affiliation Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

  ⨯
• Kyoko Moriguchi,

  Affiliation Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

  ⨯
• Hiroshi Ohno,

  Affiliation R&D Center, Biofermin Pharmaceutical Co., Ltd., Kobe, Japan

  ⨯
• Koki Taniguchi

  Affiliation Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

  ⨯